Surgery Partners(SGRY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][24] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but significantly below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][26] - Fourth quarter revenue grew 2.4% to $885 million, with same facility total revenue increasing 3.5% [24][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with 1.3% same facility case growth in the fourth quarter [7][24] - Orthopedic cases grew significantly, with total joint replacements increasing 15% in the fourth quarter and 19% year-to-date compared to the previous year [8] - The company faced challenges in three surgical hospital markets, which experienced slower case growth and shifts in payer mix, impacting overall performance [5][10] Market Data and Key Metrics Changes - The payer mix softened during the fourth quarter, with a decline in commercial patients compared to historical experience, leading to pressure on revenue [25][41] - The company noted that the pressure on payer mix was concentrated in its surgical hospitals, while its ambulatory surgical centers (ASCs) performed in line with historical trends [79] Company Strategy and Development Direction - The company remains committed to its growth strategy, focusing on organic growth, acquisitions, and de novo facility development, with a disciplined approach to capital allocation [6][12] - A portfolio optimization strategy is being executed to unlock value and drive sustained success, with plans to divest certain facilities that do not align with core strategies [15][16] - The company anticipates opening additional de novo facilities in high-growth markets, with a focus on higher acuity specialties [13][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the second half of the year but expressed confidence in the long-term growth opportunities driven by structural market dynamics [6][20] - The initial guidance for 2026 includes net revenue of $3.35 billion to $3.45 billion, representing single-digit year-over-year growth, and at least $530 million in Adjusted EBITDA [18][33] - Management emphasized the importance of addressing near-term headwinds while remaining optimistic about the structural tailwinds supporting long-term growth in the ASC market [20][36] Other Important Information - The board authorized a share repurchase program of up to $200 million, reflecting confidence in the company's future and capital allocation strategy [22][84] - The company appointed Lloyd Dean as a new director, bringing valuable healthcare experience to support growth and partnerships [23] Q&A Session Summary Question: How to think through the challenges of headwinds and payer mix dynamics? - Management highlighted the importance of their value proposition in the market and expressed confidence in their growth algorithm despite current challenges [40][41] Question: What is the weighting of issues in the three specific markets mentioned? - Management explained that the issues are distinct to each market, with plans in place to address them and a belief that these pressures are not expected to repeat [44][51] Question: How does the company plan to balance capital deployment with a leveraged balance sheet? - Management indicated a focus on maximizing shareholder value through disciplined capital allocation, including M&A, debt repayment, and share buybacks [53][56] Question: What is the breakdown between price and volume in the 3% same-store revenue guide? - Management stated that the breakdown is roughly even between price and volume [60] Question: When can positive signs be expected from physician partners regarding mix? - Management noted that improvements are expected in the back half of the year as strategies are implemented to enhance access for commercial patients [62][63]